CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MetrioPharm AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MetrioPharm AG
Europaallee 41
Phone: +41 445527190p:+41 445527190 ZUERICH, 8004  Switzerland Fax: +41 442017475f:+41 442017475
Business Summary
MetrioPharm AG is a Switzerland-based company engaged in the development of therapies based on active substances fighting bacterial and viral infections. As of December 31, 2011, the Company's product pipeline comprised two classes of drugs: MP1000 and MP2000. MP1000 constitutes a class of molecular anti-inflammatory drugs that primarily target activated (inflammatory) macrophages. MP2000 targets cardiac muscle metabolism and comprises related drug compounds, which are specific inhibitors of the CPT1 enzyme. These drugs inhibit the use of fatty acids as primary energy source of the heart muscle and shift the heart metabolism towards the use of glucose as an alternative energy source. As of December 31, 2011, Athenion AG held a 58%-stake in the Company.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Founder RudolfStaeger 1/1/2017 1/1/2017
Chief Executive Officer ThomasChristely
Founder, Chief Scientific Officer, Chief Medical Officer WolfgangBrysch 55 1/1/2022 1/1/2022
3 additional Officers and Directors records available in full report.

Business Names
Business Name
MetrioPharm AG
MP5
MP5N

General Information
Number of Employees: 7 (As of 12/31/2011)
Outstanding Shares: 209,908,275 (As of 12/31/2023)
Stock Exchange: ETR
Fax Number: +41 442017475


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024